Tirzepatide reduces obesity-associated breast cancer growth in mouse model

[News]

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

More... (https://www.news-medical.net/news/20250712/Tirzepatide-reduces-obesity-associated-breast-cancer-growth-in-mouse-model.aspx)